This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: H35.59 | Special Copayment Reduction: V209 | Coverage period: 5 years |
| B. Synonyms | LCA, Leber's congenital amaurosis, early-onset severe retinal dystrophy (EOSRD) |
| C. Adult onset | Very low likelihood of first onset in adulthood — onset immediately after birth~within the first few months of life is a defining element; first manifestation in adulthood is effectively inconsistent with this diagnosis |
| 1. History | First described by Theodor Leber in 1869; numerous causative genes identified from the late 20th to early 21st century |
| 2. Causes | Variants in more than 25 genes; CEP290, RPE65, GUCY2D, CRB1, RPGRIP1, etc. are the main causative genes |
| 3. Genetics | Mainly autosomal recessive; some autosomal dominant (IMPDH1, CRX); known causative genes explain 70~80% overall |
| 4. Epidemiology | Prevalence 2~3/100,000; about 5% of congenital visual impairment; no particular ethnic predilection |
| 5. Pathophysiology | Polygenic; RPE65 deficiency blocks the visual cycle; CEP290 variants cause ciliary dysfunction → failure of photoreceptor development |
| 6. Symptoms | Severe vision loss or blindness from birth to infancy; nystagmus; photophobia; eye poking (oculo-digital sign) |
| 7. Signs | Nystagmus, absent/markedly reduced pupillary response, strabismus, hyperopia; extinguished ERG |
| 8. Screening | Immediate referral for ERG and genetic testing for infantile nystagmus or visual unresponsiveness; early genetic testing when there is a family history |
| 9. Diagnosis | Extinguished ERG + clinical findings + molecular genetic confirmation; assess gene therapy eligibility when an RPE65 variant is confirmed |
| 10. Treatment | voretigene neparvovec (Luxturna, RPE65-LCA); low-vision rehabilitation; clinical trials for multiple genes ongoing |
| 11. Prognosis | Varies by genotype; some stable, some progressively worsening; partial functional recovery after RPE65 gene therapy |
| 12. Prevention | Genetic counseling; preimplantation genetic diagnosis; screening for associated malformations; early sensory developmental stimulation |
| References | 10 key references with PMIDs |
Leber Congenital Amaurosis (LCA) became known in 1869 when the Swiss ophthalmologist Theodor Leber first described pediatric patients showing severe vision loss at birth or in infancy. Leber clinically inferred that the disease was due to primary degeneration of the retinal photoreceptors and used the name "congenital amaurosis." In the mid-20th century, the introduction of the full-field electroretinogram (ERG) made it possible to objectively measure the loss of retinal function in LCA, and this was incorporated into the diagnostic criteria.
With the era of molecular genetics, numerous causative genes were identified from the late 1990s through the 2000s. In 1997, RPE65 gene variants were first identified as a cause of LCA, and subsequently more than 25 additional genes were discovered, including GUCY2D (LCA1), AIPL1 (LCA4), RPGRIP1 (LCA6), CRB1 (LCA8), and CEP290 (LCA10). CEP290 is currently known as the most common causative gene among LCA patients, mainly involving a deep intronic variant (c.2991+1655A>G).
2017 was a landmark year in the history of LCA treatment. For LCA caused by RPE65 variants, voretigene neparvovec (brand name Luxturna, Spark Therapeutics) received FDA approval and began to be used for the treatment of an inherited disease as the world's first gene therapy. This achievement is regarded as a milestone that demonstrated the feasibility of clinical application of gene therapy in the field of rare inherited retinal dystrophies.
LCA is a genetically highly heterogeneous disease; more than 25 causative genes have been identified to date, and these account for about 70~80% of all patients. The remaining 20~30% are presumed to be due to as yet unknown gene variants. The causative genes are distributed across diverse biological pathways involved in the development, function, and maintenance of retinal photoreceptors.
The major causative genes and their functions are as follows. CEP290 is a ciliary protein essential for formation of the photoreceptor cilium structure and accounts for about 15~20% of LCA patients of European descent. RPE65 functions as the retinoid isomerase of the visual cycle in the retinal pigment epithelium (RPE), and variants are found in about 6~16% of all LCA patients. GUCY2D (guanylate cyclase 2D) is an enzyme that synthesizes cGMP in photoreceptors; it is the cause of LCA1 and accounts for about 10~20% of the total. CRB1 is involved in maintaining cell polarity at the photoreceptor–Müller cell junction, and RPGRIP1 is required for the structure of the connecting cilium.
Other causative genes include AIPL1 (farnesylated protein chaperone), TULP1 (tubby-like protein 1), RDH12 (retinal dehydrogenase), IMPDH1, and CRX (cone-rod homeobox transcription factor). Even the same gene variant can produce different phenotypes, and variants in the same gene can be observed in both LCA and early-onset severe retinal dystrophy (EOSRD), so these two diseases are understood as the two extremes of a spectrum.
Most cases of LCA (about 90% or more) follow an autosomal recessive inheritance pattern. Autosomal dominant variants have rarely been reported, and some variants in the IMPDH1 and CRX genes are associated with dominantly inherited LCA. X-linked inheritance is very rare in LCA.
Genotype–phenotype correlations differ somewhat from gene to gene. The CEP290 c.2991+1655A>G deep intronic variant (p.Cys998X) is the most common variant in European LCA10 patients and produces a truncated protein that impairs ciliary function. GUCY2D variants generally show a stable course, with severe vision loss from birth but relatively long-term preservation of retinal structure. CRB1 variants are accompanied by structural abnormalities such as macular coloboma and retinoschisis, which aid diagnosis. RPE65 variants feature prominent night blindness and cause photoreceptor damage through a mechanism similar to vitamin A deficiency.
The frequency increases in consanguineous populations, and phenotypic variability can be observed even among siblings within the same family. Molecular genetic diagnosis provides key information for genetic counseling, assessment of treatment eligibility, and decisions about clinical trial participation.
The birth prevalence of LCA is estimated at about 2~3 per 100,000, and it accounts for about 5% of all causes of congenital or early-onset severe visual impairment. Worldwide, about 200,000 people are estimated to be affected by LCA or early-onset severe retinal dystrophy. There is no sex difference, and it occurs in all ethnic groups. Relatively high frequencies are reported in Middle Eastern and South Asian populations with high rates of consanguineous marriage.
When there is a family history, the sibling recurrence risk is 25% (autosomal recessive). Sporadic occurrence is also common, and in such cases molecular genetic diagnosis is possible even without a family history. The distribution of causative genes differs by ethnicity and region. In Europe, CEP290 and GUCY2D are the most common, while in Middle Eastern populations founder effect variants in specific genes show high frequencies.
The rate of early, accurate diagnosis has greatly improved with the widespread introduction of gene panel testing, and especially for RPE65 variants, molecular diagnosis is essential for meeting the coverage criteria for gene therapy (Luxturna). In Korea's rare disease registration, LCA is also registered as a rare disease eligible for Special Copayment Reduction.
The pathophysiology of LCA differs depending on the causative gene and can be broadly divided into failure of photoreceptor development, visual cycle disorders, ciliary dysfunction, and impaired phototransduction signaling. A common feature is that photoreceptor function is severely impaired from immediately after birth or early infancy.
In RPE65-related LCA: the RPE65 enzyme catalyzes the isomerization of all-trans-retinyl esters to 11-cis-retinol within RPE cells, which is an essential step in the visual cycle for regenerating the chromophore of the photosensitive pigment (opsin). When RPE65 function is lost, the supply of 11-cis-retinal is blocked, so rhodopsin (rods) and cone pigments cannot be regenerated, and the photoreceptors remain persistently inactivated and unable to function. Photoreceptor structure is relatively preserved initially and then gradually degenerates.
In CEP290-related LCA: CEP290 is located in the transition zone of the connecting cilium that links the photoreceptor inner segment and outer segment, and regulates intraciliary protein transport. When CEP290 function is abnormal, protein transport to the photoreceptor outer segment is impaired, leading to failure of outer segment formation and maintenance and gradual degeneration of photoreceptors. In GUCY2D deficiency, decreased cGMP synthesis in photoreceptors makes cGMP recovery after phototransduction impossible, resulting in a state of persistent photoreceptor suppression.
The most prominent clinical symptom of LCA is severe vision loss or practical blindness appearing immediately after birth or within the first few months of life. In infancy, the problem caregivers notice first is that the child does not respond to light or moving objects or does not make proper eye contact. Nystagmus is a very common early symptom, developing within the first few weeks to months of life due to the absence of visual input during the period of visual development.
Franceschetti's oculo-digital sign is a characteristic behavior of LCA in which the affected child repeatedly pokes or presses his or her own eyes with the fingers or fist. This behavior is interpreted as self-generating visual stimulation by inducing phosphenes or flashes of light through eye stimulation, and in severe long-term cases it can lead to enophthalmos. Photophobia is prominent in some genotypes (e.g., GUCY2D), with hypersensitivity to bright light.
Systemic symptoms may also be present. CEP290 variants can show phenotypes overlapping with ciliopathies such as Bardet-Biedl syndrome or Joubert syndrome, so evaluation for renal dysfunction, developmental delay, and neurological abnormalities is needed. NPHP5 (IQCB1) variants may be accompanied by nephronophthisis.
Nystagmus is an almost universal finding in LCA, appearing within the first few weeks to months of life. Pupillary responses are markedly reduced or absent (amaurotic pupil). Strabismus commonly accompanies the vision loss and inability to control ocular alignment. The most common refractive error is high hyperopia, and keratoconus develops in some patients, which is related to repeated ocular stimulation from the oculo-digital sign.
Fundus findings may appear normal initially, but retinal vascular attenuation, optic disc pallor, and bone-spicule pigmentation of the RPE may gradually appear. Macular coloboma or macular atrophy is particularly prominent with CRB1 variants. The most decisive objective finding is that on full-field ERG both scotopic and photopic responses are extinguished or reduced to unrecordable levels. This finding is essential for the diagnosis of LCA.
OCT shows marked or complete loss of the photoreceptor layer (ellipsoid zone, photoreceptor layer), the degree of which varies by genotype. Patients with GUCY2D variants may show relatively preserved retinal structure early on, which is used as a selection criterion for treatment clinical trials. Brain MRI is used to evaluate the presence of structural abnormalities such as cerebellar vermis hypoplasia (molar tooth sign in Joubert) in variants of ciliopathy-associated genes such as CEP290.
When nystagmus, absent visual responses, or unexplained reduced pupillary responses are observed in infancy, ophthalmologic evaluation together with full-field electroretinography (ERG) should be performed immediately. Infant ERG is performed under sedation, and both scotopic and photopic responses are evaluated and used as the key basis for diagnosing LCA. If loss or marked reduction of the ERG response is confirmed, molecular genetic testing is referred immediately.
In newborns with a family history (both parents carriers of the same gene), ophthalmologist examination and molecular genetic diagnosis are performed early in the neonatal period. This is because, in the case of RPE65 variants, this becomes the starting point for assessing eligibility for Luxturna treatment, and early treatment may be beneficial for photoreceptor preservation. Because newborn metabolic screening does not include LCA-specific markers, clinical clues are the starting point for screening.
For prenatal diagnosis, in families where a previous child was diagnosed with LCA, genetic diagnosis by prenatal amniocentesis or chorionic villus sampling is possible. Preimplantation genetic diagnosis (PGT-M) is also available. Meanwhile, when there are variants in ciliopathy-related genes (CEP290, NPHP5, etc.), a systemic evaluation protocol for the presence of abnormalities in other organs such as the kidneys, liver, and brain should be applied.
The diagnosis of LCA requires meeting three key clinical criteria: ① severe vision loss within the first year of life, ② nystagmus, and ③ extinguished or markedly reduced full-field ERG. ERG loss is essential for the diagnosis, and if the ERG is normal, the diagnosis of LCA should be reconsidered. The standard is then to confirm the causative gene variant by molecular genetic testing.
For molecular diagnosis, an inherited retinal dystrophy gene panel NGS covering more than 25 LCA/EOSRD-related genes is the first choice. If no variant is identified on the panel, whole-exome sequencing (WES) or whole-genome sequencing (WGS) is considered; because the CEP290 deep intronic variant (c.2991+1655A>G) may be missed by standard panels, a separate confirmatory test may be needed. RNA analysis is also used to confirm the functional significance of deep intronic variants.
A comprehensive retinal function evaluation is performed, including fundus photography, FAF, OCT, full-field ERG, multifocal ERG, visual evoked potentials (VEP), and visual field testing. Brain MRI is needed for genotypes with possible accompanying neurological abnormalities (CEP290, IQCB1, etc.). Renal ultrasound and serum renal function tests are performed to check for accompanying nephronophthisis. When biallelic pathogenic RPE65 variants are confirmed, assessment of eligibility for Luxturna treatment (confirmation of the presence of viable retinal cells) proceeds immediately.
In December 2017, the FDA approved voretigene neparvovec (Luxturna, Spark Therapeutics) for the treatment of retinal dystrophy due to biallelic pathogenic RPE65 variants. This is the first gene therapy to receive FDA approval for the purpose of treating a disease caused by a genetic defect, and the EMA also approved it in 2018. It is administered by subretinal injection, directly injecting a recombinant adeno-associated virus (rAAV2) vector carrying normal RPE65 cDNA into areas where viable retinal photoreceptors remain. Both eyes can be treated, sequentially at an interval of about 1 week.
In clinical trials after Luxturna treatment, patients showed improved ability to navigate in dim environments, improved full-field light sensitivity thresholds (full-field stimulus testing), and expanded functional visual fields, and these effects have been reported to last at least 4 years. To maximize the treatment effect, it is advantageous to treat early while many viable photoreceptors remain.
For LCA due to variants in genes other than RPE65, various clinical trials are ongoing, including an antisense oligonucleotide targeting CEP290 (LCA10) (sepofarsen, in clinical trials), CRISPR/Cas9-based in vivo gene editing (EDIT-101, targeting CEP290 variants), and LCA5-related gene therapy (Opus Genetics, phase 1/2 in 2024). In all LCA patients, it is important to introduce low-vision rehabilitation (assistive devices, Braille, orientation and mobility training, auditory aids) early and to connect families with developmental support and special education resources.
The prognosis of LCA varies considerably depending on the causative genotype. In some genotypes (GUCY2D, RPGRIP1, etc.), retinal structure is preserved relatively long, and vision may remain stable for decades. In contrast, with CRB1, CEP290, and AIPL1 variants, progressive retinal degeneration tends to proceed more quickly. Patients with RPE65 variants often progress to complete blindness by middle age if untreated, but functional improvement has been reported after Luxturna treatment.
Intelligence and general development are normal in isolated LCA, but when there are variants in ciliopathy-related genes (CEP290, etc.), renal dysfunction, neurodevelopmental delay, and other problems affect the prognosis. Repeated increases in intraocular pressure from the oculo-digital sign can cause keratoconus and enophthalmos, so early intervention is necessary. Overall, with appropriate low-vision rehabilitation, special education, and social support, independent living at a level that permits participation in social life is possible.
Currently, primary prevention of LCA (preventing genetic occurrence) is possible only through genetic counseling and preimplantation genetic diagnosis (PGT-M) or prenatal diagnosis. Genetic counseling is provided to siblings of confirmed patients or to carrier couples planning a family, and information on reproductive options is provided when needed. Avoiding consanguineous marriage contributes to reducing the risk of autosomal recessive genetic diseases.
From the perspective of secondary prevention (inhibiting disease progression), safety measures to prevent repeated ocular pressure from the oculo-digital sign (protective eyewear, behavioral intervention) help prevent corneal deformation. Because strong ultraviolet exposure can theoretically aggravate retinal damage, wearing UV-blocking lenses is recommended. In genotypes with possible accompanying ciliopathy, regular monitoring of renal, hepatic, and cardiac function should allow early detection and management of complications.
Information on new gene therapy clinical trials should be continuously provided to patients and caregivers, and especially in patients with RPE65 variants, eligibility conditions for Luxturna (presence of viable photoreceptors) should be evaluated early so that the window for treatment is not missed. Connecting children with visual impairment to early intervention education programs to promote sensory and motor development is also part of preventive care.